Editor Profile

Mark V. Dahl, MD

Associate Editor

About the NEJM Journal Watch Dermatology Board

Mark V. Dahl, MD, is currently Professor of Dermatology, College of Medicine, Mayo Clinic, and Senior Consultant in the Department of Dermatology at Mayo Clinic in Scottsdale/Phoenix, Arizona. He has served as President of the American Academy of Dermatology and as Vice President of the Society for Investigative Dermatology. He is the founder of Camp Discovery, a camping program for children with severe skin diseases. Dr. Dahl is a recipient of the Gold Medal, the American Academy of Dermatology's highest honor, and was named a Master Dermatologist by the organization in 2006. His research has focused on immunology, infections, and inflammatory diseases of the skin, including studies related to immunodeficiency, chemotaxis, granuloma annulare, immunofluorescence, bullous diseases, psoriasis, cutaneous irritation, allergy, rosacea, the epidermal acetylcholine network, and cutaneous fungal infections. Dr. Dahl joined the NEJM Journal Watch Dermatology board in 2007 and served until the publication’s closure in 2016.


Consultant / Advisory board

Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics


Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards


Leadership positions in professional societies

National Rosacea Society (Chairman, Medical Board)

Summaries by Mark Dahl

  • March 15, 2016

    Metronidazole vs. IvermectinFree

    1. Mark V. Dahl, MD

    Which drug for remission of rosacea?

  • February 22, 2016

    What Say?Free

    1. Mark V. Dahl, MD

    The International League of Dermatological Societies presents a revised glossary for the description of cutaneous lesions.

  • February 5, 2016

    Risks for Second Basal Cell Carcinomas

    1. Mark V. Dahl, MD

    Many people with a BCC will develop another. What is the magnitude of risk, and what factors increase that risk?

  • January 22, 2016

    Ice the Pain

    1. Mark V. Dahl, MD

    Skin cooling induced month-long diminution of mechanical and thermal pain sensation but did not affect perception of itch.

  • January 22, 2016

    Risk Loci for Atopic Dermatitis

    1. Mark V. Dahl, MD

    Twenty-seven loci were associated with AD, including 16 previously known and 11 new loci.

  • January 14, 2016

    Oxybutynin for Hyperhidrosis

    1. Mark V. Dahl, MD

    Excess sweating was improved significantly compared with placebo.